Active, Not Recruiting
The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis - IM101-686
Updated: 17 April, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - 18 years of age at enrollment - Confirmed diagnosed with RA - Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site Exclusion Criteria: - Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels - Was followed at the site for less than 1 year since biologic treatment initiation - Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
